Anlon Healthcare is fundamentally a chemistry company built on a single family of pain-relief molecules. Incorporated in 2013 in Rajkot, Gujarat, and listed in 2025, it began by mastering the tricky methylation and Friedel-Crafts reactions needed to make high-purity “profane-series” anti-inflammatory drugs, then used that expertise to become one of the few Indian manufacturers of APIs (active pharmaceutical ingredients) like Loxoprofen and Ketoprofen. Its recurring approach is to pursue backward integration from day one-making its own key starting materials so it never depends on Chinese raw-material suppliers-and to select only those products where it can achieve better process chemistry than its Chinese competitors.
Business segments
Three engines at different stages-a specialised API and intermediate factory that generates the cash, a fledgling industrial-chemicals sideline that fills the reactors, and a newly acquired finished-dosage business that turns the company’s own molecules into tablets.
1. Pharmaceutical intermediates and APIs: the pain-management specialist
The company makes the active molecules that go into anti-inflammatory painkillers, selling them to global drugmakers who then formulate the finished tablets-and for its anchor molecule it supplies the only Indian-made intermediate to the company that controls roughly 60% of the world market.
- Backward-integrated from the first reaction - for every key molecule, Anlon manufactures its own KSM (key starting material) domestically; none are imported from China, so customers get a supply chain that aligns with their “China Plus One” policies.
- A narrow, deep catalogue - the portfolio spans 65 commercialised products, but the top five contribute about 78% of revenue, and the three core APIs-Loxoprofen Sodium, Ketoprofen, and Dexketoprofen Trometamol-address five pain and inflammation conditions between them.
- The Minarini relationship is the anchor - the Italian company Minarini holds roughly 60% of the global dexketoprofen tablet market, and Anlon is the only Indian manufacturer supplying them the N-1 intermediate, which means Anlon’s molecule indirectly reaches 50-60% of the world’s dexketoprofen patients.
- A multipurpose plant, not a dedicated line - the Rajkot facility has glass-lined and stainless-steel reactors that can scale from 20-litre to 200-litre assemblies and switch between products, giving it an installed capacity of 1,400-1,600 metric tonnes per annum without being locked into any single molecule.
- Regulatory approvals open the regulated markets - the company holds a CEP from the European EDQM for Ketoprofen, ANVISA approval in Brazil for loxoprofen sodium dihydrate, and NMPA approval in China for Loxoprofen, and has filed 21 Drug Master Files globally, with five to six products already in commercial supply to regulated markets as of mid-2026.
2. Industrial and fine chemicals: filling the plant with high-volume molecules
A younger, less regulated sideline that makes bromine-based chemicals for agrochemical and paint industries, using the same multipurpose reactors and adding ballast to the revenue mix.
- De-risking through volume - the segment was launched to complement the pharma business with products that carry fewer regulatory hurdles and offer higher volume potential, so the plant is not solely dependent on the lumpy, approval-heavy API cycle.
- Acquired, not built from scratch - the entry came through the acquisition of Apiqo Organics, whose top three molecules include methyl propyl bromide, isopropyl bromide, and a KSM for pesticides made via bromination, bringing an extra 700-800 metric tonnes per annum of ready capacity.
3. Finished dosage formulations: turning APIs into tablets
A newly acquired subsidiary that gives Anlon the ability to sell finished tablets and capsules-not just the powder inside them-transforming the company from an ingredient supplier into a complete pharmaceutical provider.
- Bought, not built - in May 2026 Anlon took a 63.98% controlling stake in Remember India Health Links (renamed Anlon Medicos), a company that manufactures, packs, and sells finished pharmaceutical products such as tablets and capsules.
- A dossier library comes with the deal - the acquisition provides access to more than 30 finished-dosage dossiers, which are the regulatory files needed to sell formulated drugs in various markets, shortening the time it would take to develop them in-house.
Group structure and partners
The listed parent company sits above three operating subsidiaries acquired in a nine-month burst, plus two more majority-owned entities being incorporated to enter medical devices and biologics.
- Apiqo Organics (67.48% stake, acquired January 2026) - manufactures pharmaceutical intermediates, industrial and fine chemicals, and inorganic chemicals, adding 700-800 metric tonnes per annum of manufacturing capacity.
- Bizotic Lifescience (56.67% stake, acquired March 2026) - used for backward integration, making KSMs like ketonitrile for ketoprofen and BMPP for loxoprofen, as well as APIs such as artemether and rifaximin.
- Anlon Medicare (55% stake, incorporation pending Registrar of Companies approval) - a new subsidiary being set up to manufacture surgical implants and medical devices, extending the pain-management franchise into the tools used in orthopaedic procedures.
- Anlon Biologics (65% stake, incorporation subject to Registrar of Companies approval) - a new subsidiary for peptides, biosimilars, and biological compositions, marking a long-term bet on complex large-molecule therapies.
- Key external partner - Minarini of Italy, which holds roughly 60% of the global dexketoprofen tablet market and relies on Anlon as its sole Indian supplier of the N-1 intermediate.